Article
Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS.
Clinical pharmacology and therapeutics - 1 Feb 2017
Monnet E, Lapeyre G, Poelgeest E van, Jacqmin P, Graaf K de, Reijers J, Moerland M, Burggraaf J, Min C de
Abstract excerpt
Toll-like receptor-4 (TLR4) pathways are major contributors to pathological inflammatory responses induced by tissue damage. NI-0101 is the first monoclonal antibody (mAb) blocking TLR4 signaling. This activity is independent of the ligand type and concentration, therefore, potentially blocking any TLR4 ligands. A phase I single ascending dose study was conducted in 73 healthy volunteers to evaluate NI-0101...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.